Slow Release Depot Therapy

The anti-cancer compound drug formed by the combination of sustained-release formulation, chemotherapy drug (dual drug), and immune adjuvant is directly injected into the tumor and embedded in the tumor under the guidance of CT, ultrasound, or endoscopy. The anti-cancer drug is gradually released within 7-20 days, killing cancer cells, avoiding the toxic side effects of the drug on the whole body and achieving the goal of eliminating the tumor; The self tumor antigens released by cancer cells killed by compound drugs at the same time, with the assistance of immune adjuvants, activate the systemic immune response of the body, thereby playing a role in clearing recurrent or metastatic cancer cells. Direct physical targeted targeted targeted killing and decapitation therapy can be performed for malignant tumors and metastatic lesions in various parts of the body, suitable for early, middle, and late stage solid tumors in all parts of the body. This therapy has obtained patented technologies in China, the United States, and Australia. Since its application in 1998, it has treated over 80000 cancer patients and achieved good treatment results!